deferoxamine

Summary

Summary: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Top Publications

  1. ncbi Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat
    Thomas Freret
    CNRS UMR 6185, Cyceron, University of Caen Basse Normandie, Bvd H Becquerel F 14074 Caen cedex, France
    Eur J Neurosci 23:1757-65. 2006
  2. pmc Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy
    Alessia Pepe
    Cardiovascular MR Unit, Fondazione G, Monasterio CNR Regione Toscana and Institute of Clinical Physiology, Pisa, Italy
    J Cardiovasc Magn Reson 15:1. 2013
  3. ncbi Iron chelation via deferoxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst
    Helen L Collins
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    J Immunol 168:3458-63. 2002
  4. ncbi The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats
    S Y Saad
    Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Pharmacol Res 43:211-8. 2001
  5. ncbi Intralysosomal iron chelation protects against oxidative stress-induced cellular damage
    Tino Kurz
    Division of Pharmacology, Faculty of Health Sciences, Linkoping University, Sweden
    FEBS J 273:3106-17. 2006
  6. ncbi Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
    M Domenica Cappellini
    Universita di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico corrected IRCCS, Milan, Italy
    Blood 118:884-93. 2011
  7. pmc Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function
    Yanxin Zhao
    Department of Neurology, Center for Neural Development and Disease, The Interdepartmental Graduate Program in Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Cereb Blood Flow Metab 31:1412-23. 2011
  8. ncbi A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major
    Yesim Aydinok
    Ege University, Faculty of Medicine, Department of Pediatric Hematology 35100 Bornova, Izmir, Turkey
    Haematologica 92:1599-606. 2007
  9. pmc Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
    Francisco Alpendurada
    Royal Brompton and Harefield NHS Foundation Trust, London, UK
    J Cardiovasc Magn Reson 14:8. 2012
  10. ncbi The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
    J Gao
    Iron Metabolism and Chelation Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, New South Wales, 2050 Australia
    Blood 98:842-50. 2001

Detail Information

Publications328 found, 100 shown here

  1. ncbi Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat
    Thomas Freret
    CNRS UMR 6185, Cyceron, University of Caen Basse Normandie, Bvd H Becquerel F 14074 Caen cedex, France
    Eur J Neurosci 23:1757-65. 2006
    ..In order to strengthen the expression of these hypoxia-inducible factors, we administered deferoxamine, an iron chelator known to stabilize HIF-1alpha protein expression, and examined its effects on the functional ..
  2. pmc Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy
    Alessia Pepe
    Cardiovascular MR Unit, Fondazione G, Monasterio CNR Regione Toscana and Institute of Clinical Physiology, Pisa, Italy
    J Cardiovasc Magn Reson 15:1. 2013
    ..was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow ..
  3. ncbi Iron chelation via deferoxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst
    Helen L Collins
    Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    J Immunol 168:3458-63. 2002
    ..Thus, altering the equilibrium of intracellular Fe influences the course of infection to the benefit of the pathogen...
  4. ncbi The preventive role of deferoxamine against acute doxorubicin-induced cardiac, renal and hepatic toxicity in rats
    S Y Saad
    Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Pharmacol Res 43:211-8. 2001
    The iron chelating activity of deferoxamine (DFO) has been exploited to obtain protection against the peroxidative damage in rat heart which was induced by the administration of an acute dose of doxorubicin (DXR, 25 mg x kg(-1), i.v.)...
  5. ncbi Intralysosomal iron chelation protects against oxidative stress-induced cellular damage
    Tino Kurz
    Division of Pharmacology, Faculty of Health Sciences, Linkoping University, Sweden
    FEBS J 273:3106-17. 2006
    ....
  6. ncbi Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
    M Domenica Cappellini
    Universita di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico corrected IRCCS, Milan, Italy
    Blood 118:884-93. 2011
    ..trial entered a 4-year extension study, either continuing on deferasirox (deferasirox cohort) or switching from deferoxamine to deferasirox (crossover cohort). Of 555 patients who received ≥ 1 deferasirox dose, 66...
  7. pmc Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function
    Yanxin Zhao
    Department of Neurology, Center for Neural Development and Disease, The Interdepartmental Graduate Program in Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Cereb Blood Flow Metab 31:1412-23. 2011
    ..Prolyl hydroxylase inhibitors (PHIs), such as deferoxamine (DFO), reduce stroke volume when administered at high doses in the peristroke period, which is largely mediated ..
  8. ncbi A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major
    Yesim Aydinok
    Ege University, Faculty of Medicine, Department of Pediatric Hematology 35100 Bornova, Izmir, Turkey
    Haematologica 92:1599-606. 2007
    ..The aim of this prospective, randomized, 1-year study was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations of parenteral desferrioxamine (DFO) with oral DFP...
  9. pmc Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
    Francisco Alpendurada
    Royal Brompton and Harefield NHS Foundation Trust, London, UK
    J Cardiovasc Magn Reson 14:8. 2012
    Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF)...
  10. ncbi The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression
    J Gao
    Iron Metabolism and Chelation Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, New South Wales, 2050 Australia
    Blood 98:842-50. 2001
    ..Failure to translate these cell-cycle inhibitors may contribute to dysregulation of the cell cycle after exposure to chelators. (Blood. 2001;98:842-850)..
  11. ncbi Growth inhibition of bloodstream forms of Trypanosoma brucei by the iron chelator deferoxamine
    Tanja Breidbach
    Abteilung Parasitologie, Hygiene Institut der Ruprecht Karls Universität, Im Neuenheimer Feld 324, D 69120 Heidelberg, Germany
    Int J Parasitol 32:473-9. 2002
    Treatment of bloodstream forms of Trypanosoma brucei with the iron chelator deferoxamine inhibits the proliferation of the parasites...
  12. ncbi The expanded clinical spectrum of deferoxamine retinopathy
    Robert Haimovici
    Department of Ophthalmology, Boston University School of Medicine, DOB 10 720 Harrison Avenue, Boston, MA 02118, USA
    Ophthalmology 109:164-71. 2002
    To describe early and unusual features in 16 patients with deferoxamine-induced retinal toxicity and to assess the role of diagnostic tests in the diagnosis and management of patients with the disorder.
  13. ncbi Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial
    Patrick B Walter
    Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
    Haematologica 93:817-25. 2008
    We assessed whether oxidant-stress and inflammation in beta-thalassemia could be controlled by the novel oral iron chelator deferasirox as effectively as by deferoxamine.
  14. pmc Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury
    Jin Yul Lee
    Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    J Cereb Blood Flow Metab 30:1793-803. 2010
    ..hemorrhage (SAH), examine the relationship between iron and neuroglial cell changes, and determine whether deferoxamine (DFX) can reduce SAH-induced injury...
  15. pmc Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke
    Leah R Hanson
    Alzheimer s Research Center at Regions Hospital, HealthPartners Research Foundation, St Paul, Minnesota 55101, USA
    J Pharmacol Exp Ther 330:679-86. 2009
    b>Deferoxamine (DFO) is a high-affinity iron chelator approved by the Food and Drug Administration for treating iron overload...
  16. pmc Cerenkov luminescence imaging of medical isotopes
    Alessandro Ruggiero
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 51:1123-30. 2010
    ..Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies...
  17. ncbi Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells
    Yuncheng Wu
    Department of Neurology, Shanghai First People s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, PR China
    Neurochem Int 57:198-205. 2010
    ..b>Deferoxamine is one of iron chelators that may accumulate HIF-1 alpha due to the decreased degradation of HIF-1 alpha via ..
  18. ncbi Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats
    Tomohito Hishikawa
    Department of Neurological Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Neurosurgery 62:232-40; discussion 240-1. 2008
    ..the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental ..
  19. ncbi Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38
    Alexa Klettner
    University of Kiel, University Medical Center, Department of Ophthalmology, Germany
    Cutan Ocul Toxicol 29:122-9. 2010
    b>Deferoxamine mesylate is clinically used as a chelating agent but might induce retinopathy. To evaluate its effect on the retinal pigment epithelium (RPE), porcine RPE cells were stimulated with deferoxamine...
  20. pmc Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging
    Alessia Pepe
    Magnetic Resonance Imaging Unit, Fondazione G Monasterio, C N R Regione Toscana, Pisa, Italy
    Haematologica 96:41-7. 2011
    ....
  21. pmc Ascorbate and deferoxamine administration after chlorine exposure decrease mortality and lung injury in mice
    Sotirios G Zarogiannis
    Department of Anesthesiology, School of Medicine and Public Health, University of Alabama at Birmingham, 35294, USA
    Am J Respir Cell Mol Biol 45:386-92. 2011
    ..Ascorbate and deferoxamine were administered intramuscularly every 12 hours and by nose-only inhalation every 24 hours for 3 days starting ..
  22. pmc Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles
    Xinguo Jiang
    Division of Pulmonary Critical Care, Department of Medicine, VA Palo Alto Health Care System Stanford University School of Medicine, Stanford, CA, USA
    Biomaterials 35:803-13. 2014
    ..b>Deferoxamine mesylate (DFO) is an FDA-approved iron chelator which has been shown to upregulate cellular HIF-1α...
  23. pmc Standardized methods for the production of high specific-activity zirconium-89
    Jason P Holland
    Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY 10065, USA
    Nucl Med Biol 36:729-39. 2009
    ..The detailed methods described can be easily translated to other radiochemistry facilities and will facilitate the use of (89)Zr in both basic science and clinical investigations...
  24. ncbi Desferrioxamine-mediated iron uptake in Saccharomyces cerevisiae. Evidence for two pathways of iron uptake
    C W Yun
    Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    J Biol Chem 275:10709-15. 2000
    ..These data indicate that S. cerevisiae has two pathways for ferrrioxamine-mediated iron uptake, one occurring at the plasma membrane and the other occurring in an intracellular compartment...
  25. ncbi Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice
    Soichiro Tajima
    Dept of Pharmacology, University of Tokushima Graduate School of Health Biosciences, 3 18 15 Kuramoto cho, Tokushima, Japan
    Am J Physiol Endocrinol Metab 302:E77-86. 2012
    ..Eight-week-old KKAy mice were divided into two groups and treated with deferoxamine (DFO), an iron chelator agent, or a vehicle for 2 wk...
  26. ncbi Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS
    Sebastian Philipp
    Dept of Physiology, Univ of South Alabama College of Medicine, Mobile, AL 36688, USA
    Am J Physiol Heart Circ Physiol 290:H450-7. 2006
    ..Hence, DFO and EDHB stimulate NO-dependent activation of PKG to open mitoK(ATP) channels and produce ROS, which act as second messengers to trigger entrance into the preconditioned state...
  27. ncbi Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model
    Fabia Febbraro
    CNS Disease Modeling Group, Department of Biomedicine, Aarhus University, DK 8000 Aarhus C, Denmark
    Exp Neurol 247:45-58. 2013
    ..Here, we investigate the possible neuroprotective effect of the iron chelator deferoxamine in vivo to elucidate whether iron chelation can provide meaningful therapy for Parkinson's disease...
  28. ncbi Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease
    Chuang Guo
    Department of Pathophysiology, China Medical University, Shenyang, China
    Neurobiol Aging 34:562-75. 2013
    ..We evaluated the effects of intranasal administration of the high-affinity iron chelator deferoxamine (DFO) on Aβ neuropathology and spatial learning and memory deficits created in this AD model...
  29. ncbi Cold induces catalytic iron release of cytochrome P-450 origin: a critical step in cold storage-induced renal injury
    Hong Huang
    Department of Medicine, University of Mississippi Medical Center, Jackson 39216 4505, USA
    Am J Transplant 2:631-9. 2002
    ..P-450 inhibitors significantly reduced cold-induced BDI release. Furthermore, cimetidine and iron chelator deferoxamine (DFO) significantly reduced cold-induced cell injury, suggesting a role for P-450-derived iron in cold-induced ..
  30. pmc Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
    Gillian C Smith
    CMR Unit, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK
    J Cardiovasc Magn Reson 13:34. 2011
    ..Deferiprone has been reported to be superior to deferoxamine for the removal of cardiac iron and improvement in left ventricular (LV) function but little is known of their ..
  31. ncbi Histidine-induced injury to cultured liver cells, effects of histidine derivatives and of iron chelators
    U Rauen
    Institut fur Physiologische Chemie, Universitatsklinikum, Hufelandstr 55, 45122, Essen, Germany
    Cell Mol Life Sci 64:192-205. 2007
    ..and by the membrane-permeable iron chelators 2,2'-dipyridyl, 1,10-phenanthroline, LK 614, LK 616 and deferoxamine. Thus, histidine-induced cell injury appears to be mediated by an iron-dependent formation of reactive oxygen ..
  32. ncbi Improvement of the cold storage of isolated human hepatocytes
    Gesine Pless
    Institut fur Physiologische Chemie, Universitatsklinikum Essen, Essen, Germany
    Cell Transplant 21:23-37. 2012
    ..Cold-induced injury could be significantly reduced by the addition of the iron chelators deferoxamine and LK 614...
  33. ncbi Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function
    Yasumasa Ikeda
    Department of Pharmacology, University of Tokushima Graduate School of Health Biosciences, 3 18 15 Kuramoto cho, Tokushima 770 8503, Japan
    Atherosclerosis 215:339-47. 2011
    b>Deferoxamine (DFO), an iron chelator for disorders of excess iron, upregulates the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2), indicating that it affects angiogenesis...
  34. pmc The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent
    Ehud Banin
    Department of Microbiology, School of Medicine, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 105:16761-6. 2008
    ..The use of DFO-Ga as a Trojan horse delivery system that interferes with iron metabolism shows promise as a treatment for P. aeruginosa infections...
  35. pmc p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
    Lars R Perk
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 37:250-9. 2010
    ..To enable widespread use of (89)Zr-immuno-PET, we now introduce the novel BFC p-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS) and compare its performance in (89)Zr-immuno-PET with the reference BFC TFP-N-sucDf...
  36. pmc Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab
    Jason P Holland
    Radiochemistry Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 5:e8859. 2010
    ..In addition, pharmacodynamic studies on HER2/neu expression levels in response to therapeutic doses of PU-H71 (a specific inhibitor of heat-shock protein 90 [Hsp90]) were conducted...
  37. ncbi Pathways for the regulation of interferon-gamma-inducible genes by iron in human monocytic cells
    Horst Oexle
    Department of Internal Medicine, University Hospital Innsbruck, Austria
    J Leukoc Biol 74:287-94. 2003
    ..Thus, iron perturbations regulate IFN-gamma effector pathways by transcriptional and post-transcriptional mechanisms, indicating that iron rather interferes with IFN-gamma signal-transduction processes...
  38. ncbi Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage
    Takehiro Nakamura
    Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan 48109 0532, USA
    J Neurosurg 100:672-8. 2004
    ..In the present study the authors investigate whether deferoxamine, an iron chelator, can reduce ICH-induced brain injury.
  39. ncbi Cytosolic aconitase and ferritin are regulated by iron in Caenorhabditis elegans
    Brett L Gourley
    Eccles Program in Human Molecular Biology and Genetics and Department of Medicine, Division of Hematology, University of Utah, Salt Lake City, Utah 84112, USA
    J Biol Chem 278:3227-34. 2003
    ..Excess iron did not significantly alter worm development but did shorten their life span. These studies indicated that iron homeostasis in C. elegans shares some similarities with those of vertebrates...
  40. ncbi Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
    M Ohh
    Department of Medicine, Brigham and Womens Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Cell Biol 2:423-7. 2000
    ..These results strengthen the link between overaccumulation of HIF and development of VHL disease...
  41. ncbi The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells
    S M Wood
    Erythropoietin Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    J Biol Chem 271:15117-23. 1996
    ....
  42. ncbi Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia
    Maria Domenica Cappellini
    Fondazione Policlinico IRCCS, Universitd di Milano, Milan, Italy
    Clin Ther 29:909-17. 2007
    Iron chelation therapy (ICT) with deferoxamine (DFO), the current standard for the treatment of iron overload in patients with transfusion-dependent disorders such as beta-thalassemia, requires regular subcutaneous or intravenous ..
  43. ncbi Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway
    Kyung Jin Woo
    Department of Immunology and Chronic Disease Research Center and Institute for Medical Science, School of Medicine, Keimyung University, 194 DongSan Dong Jung Gu, Taegu 700 712, South Korea
    Biochem Biophys Res Commun 343:8-14. 2006
    ..Together, our findings suggest that iron metabolism may regulate stabilization of HIF-1alpha protein by modulating cyclooxygenase-2 signaling pathway...
  44. ncbi Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
    Kallistheni Farmaki
    Transfusion Department and Thalassaemia Unit, General Hospital of Corinth, Leoforos Athinon 53, Corinth 20100, Greece
    Br J Haematol 148:466-75. 2010
    ..These results suggest that intensive combined chelation normalized patients' iron load and thereby prevented and reversed cardiac and multiple endocrine complications associated with transfusion iron overload...
  45. pmc Ferrioxamine-mediated Iron(III) utilization by Salmonella enterica
    R A Kingsley
    Department of Microbiology and Immunology, University of Leicester, Leicester LE1 9HN, United Kingdom
    Appl Environ Microbiol 65:1610-8. 1999
    ..In addition, a foxA mutant was markedly attenuated in mice inoculated by either the intragastric or intravenous route. Mice inoculated with the foxA mutant were protected against subsequent challenge by the foxA+ parent strain...
  46. ncbi Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Br J Haematol 145:245-54. 2009
    ..randomized open-label trial was designed to assess the effectiveness of long-term sequential deferiprone-deferoxamine (DFO-DFP) versus DFP alone to treat thalassaemia major (TM)...
  47. pmc Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion
    T Y Y Lai
    Br J Ophthalmol 90:243-4. 2006
  48. ncbi Deferoxamine decreases the excitatory amino acid levels and improves the histological outcome in the hippocampus of neonatal rats after hypoxia-ischemia
    Georgios Papazisis
    Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, P O Box 1532, 54006 Thessaloniki, Greece
    Pharmacol Res 57:73-8. 2008
    ..b>Deferoxamine (DFO), a chelator of non-protein-bound iron, has been shown to inhibit lipid peroxidation and hydroxyl radical ..
  49. ncbi Improvement of the cold storage of blood vessels with a vascular preservation solution. Study in porcine aortic segments
    Timo Wille
    Institut fur Physiologische Chemie, Universitatsklinikum, Essen, Germany
    J Vasc Surg 47:422-31. 2008
    ..Hypothesizing that this iron-dependent cold-induced injury might also occur in the endothelium of intact vessels, we here set out to optimize the hypothermic storage of blood vessels...
  50. ncbi Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice
    Amanda Fortes Francisco
    Núcleo de Pesquisas em Ciências Biológicas, Instituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Rua Costa Sena, 171, Campus Universitário Morro do Cruzeiro Cep 35 400 000 Ouro Preto, MG, Brazil
    Exp Parasitol 120:314-9. 2008
    ..The results demonstrate that modification in iron stores increases BZ efficacy...
  51. ncbi Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 42:247-51. 2009
    ..was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment...
  52. ncbi Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial
    Elliott Vichinsky
    Children s Hospital and Research Center, Oakland, CA 94609, USA
    Acta Haematol 119:133-41. 2008
    ..However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that can negatively impact quality of life and adherence to treatment.
  53. ncbi A widespread deferoxamine-mediated iron-uptake system in Vibrio vulnificus
    Choon Mee Kim
    Research Center for Resistant Cells, Chosun University Medical School, 375 Seosuk dong, Dong Gu, Gwangju, Republic of Korea
    J Infect Dis 196:1537-45. 2007
    Vibrio vulnificus can use the standard iron chelator deferoxamine (Desferal) for efficient iron-uptake via the specific receptor DesA, which is encoded by desA...
  54. ncbi Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
    Fadi H Mourad
    Department of Internal Medicine, The American University of Beirut Medical Centre, Beirut, Lebanon
    Br J Haematol 121:187-9. 2003
    ..Main side-effects were skin reactions (DFX alone), nausea and arthralgia (combined therapy). As chelation therapy, the combined protocol was as effective as DFX five times weekly...
  55. ncbi Oxidative damage of DNA by the reaction of amino acid with methylglyoxal in the presence of Fe(III)
    Jung Hoon Kang
    Department of Genetic Engineering, Chongju University, Chongju 360 764, South Korea
    Int J Biol Macromol 33:43-8. 2003
    ..This mechanism, in part, may provide an explanation for the deterioration of organs under diabetic conditions...
  56. ncbi Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy
    Tianen Yang
    Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
    J Lab Clin Med 142:332-40. 2003
    To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (..
  57. ncbi A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia
    Renzo Galanello
    Department of Biomedical Science and Biotechnology, University of Cagliari, Ospedale Microcitemico, Italy
    Haematologica 91:1241-3. 2006
    We compared the safety and efficacy of alternating deferoxamine and deferiprone with that of deferoxamine monotherapy...
  58. ncbi Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity
    Mee Jung Park
    Dept of Forensic Science, National Institute of Scientific Investigation, Yangchon ku, Seoul, 158 707, Korea
    Brain Res 1109:176-82. 2006
    ..This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity...
  59. ncbi Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
    Bernard A Davis
    Department of Haematology, Royal Free and University College Medical School, and Department of Research and Development, University College London Hospitals, United Kingdom
    Blood 104:263-9. 2004
    ..percentage units, intensified chelation therapy was recommended (21 with subcutaneous and 13 with intravenous deferoxamine). All 27 patients who complied with intensification survived, whereas the 7 who did not comply died (P <...
  60. ncbi Desferrioxamine attenuates minor lung injury following surgical acute liver failure
    G G Kostopanagiotou
    Second Dept of Anaesthesiology, University of Athens School ofMedicine, Attikon Hospital, Athens, Greece
    Eur Respir J 33:1429-36. 2009
    ..The limited activity of PLA(2) and the attenuation of pneumonocyte necrosis could represent beneficial mechanisms by which DFX improves alveolar-capillary membrane permeability and prevents alveolar space collapse...
  61. ncbi Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias
    Peter D Jensen
    Department of Hematology and Center for Nuclear Magnetic Resonance, Aarhus University Hospital, Denmark
    Blood 101:91-6. 2003
    ..Our findings may be helpful in establishing criteria for safety from complications of transfusional iron overload...
  62. ncbi The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice
    Vladislav Eybl
    Department of Pharmacology and Toxicology, Charles University Faculty of Medicine in Pilsen, Karlovarska 48, 301 66 Pilsen, Czech Republic
    Toxicol Lett 128:169-75. 2002
    ..was used in this study to produce an iron-overload model in experimental animals for evaluating the effect of deferoxamine (DFO) and deferiprone (L1) on tissue-stored iron, induced lipid peroxidation (LP) and parameters of oxidative ..
  63. ncbi Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease
    L B Jordan
    Sickle Cell Disease Association of America, Inc, Baltimore, MD, USA
    J Clin Pharm Ther 37:173-81. 2012
    ..Two iron chelating agents are currently available in the United States: Deferoxamine (DFO) is an injectable formulation, and deferasirox (Exjade(®) ) is an oral suspension...
  64. ncbi Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients
    Gaetano Restivo Pantalone
    Unità Operativa Complessa Ematologia II con Talassemia, Azienda Ospedaliera Ospedali Riuniti Villa Sofia, Vincenzo Cervello, Palermo, Italia
    Hemoglobin 35:206-16. 2011
    ..Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1)...
  65. ncbi Morphological evidence of ototoxicity of the iron chelator deferoxamine
    B Ryals
    Department of Communication Sciences and Disorders, James Madison University, Harrisonburg, VA 22807, USA
    Hear Res 112:44-8. 1997
    ..ototoxicity by iron chelators led us to re-examine experimental material from a previously unpublished study of deferoxamine. Deferoxamine was injected i.m. into adult Japanese quail at either 300 or 750 mg/kg body weight for 30 days...
  66. pmc Deferoxamine reverses radiation induced hypovascularity during bone regeneration and repair in the murine mandible
    Aaron S Farberg
    Craniofacial Research Laboratory, University of Michigan Medical School, Ann Arbor, MI 48109 0219, USA
    Bone 50:1184-7. 2012
    b>Deferoxamine (DFO) is an iron-chelating agent that has also been shown to increase angiogenesis...
  67. ncbi Modulation of inflammatory response after spinal cord trauma with deferoxamine, an iron chelator
    Irene Paterniti
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, Gazzi, Messina, Italy
    Free Radic Res 44:694-709. 2010
    The standard iron-chelator deferoxamine is known to reduce neurological deficits...
  68. ncbi Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice
    J M Fine
    Alzheimer s Research Center, HealthPartners Research Foundation at Regions Hospital, St Paul, MN 55101, USA
    Exp Brain Res 219:381-90. 2012
    b>Deferoxamine (DFO), a metal chelator, has been previously reported to slow the loss of spatial memory in a mouse model of amyloid accumulation when delivered intranasally (IN)...
  69. pmc Localized deferoxamine injection augments vascularity and improves bony union in pathologic fracture healing after radiotherapy
    Alexis Donneys
    Craniofacial Research Laboratory, Plastic Surgery Section, University of Michigan, Ann Arbor, MI 48109 4215, USA
    Bone 52:318-25. 2013
    ..Experimental studies have shown that deferoxamine (DFO), an iron-chelating agent, bolsters vascularity and subsequently enhances normal fracture healing when ..
  70. ncbi Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis
    Omar J Cassol
    Programa de Pos Graduacao em Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, SC, Brazil
    Neurochem Res 35:515-21. 2010
    ..in the brain of rats after cecal ligation and perforation (CLP) and that a combination of N-acetylcysteine/deferoxamine (NAC/DFX), taurine and RC-3095 were shown to be an effective treatment of sepsis, we investigated whether the ..
  71. pmc Deferoxamine expedites consolidation during mandibular distraction osteogenesis
    Alexis Donneys
    Craniofacial Research Laboratory, Plastic Surgery Section, University of Michigan, Ann Arbor, MI, USA
    Bone 55:384-90. 2013
    ..b>Deferoxamine (DFO) is an angiogenic activator that triggers the HIF-1α pathway through localized iron depletion...
  72. ncbi Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain
    Chuang Guo
    College of Life and Health Sciences, Northeastern University, Shenyang 110004, PR China
    Neurochem Int 62:165-72. 2013
    ..More importantly, elucidation of DFO mechanism in suppressing tau phosphorylation may provide insights for developing therapeutic strategies to combat AD...
  73. ncbi Deferoxamine preconditioning potentiates mesenchymal stem cell homing in vitro and in streptozotocin-diabetic rats
    R Najafi
    Tehran University of Medical Sciences, School of Medicine, Razi Drug Research Center, Department of Pharmacology, Tehran, Iran
    Expert Opin Biol Ther 13:959-72. 2013
    ..There is evidences showing that deferoxamine (DFO), an iron chelator, increases the mobilization and homing of progenitor cells through increasing the ..
  74. ncbi Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results
    Isabelle Thuret
    CHU Timone, Marseille, France
    Hematology 14:315-22. 2009
    b>Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions...
  75. pmc Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
    Mark A Tanner
    Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK
    J Cardiovasc Magn Reson 10:12. 2008
    In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur...
  76. pmc Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage
    Magdy Selim
    Department of Neurology, Stroke Division, Beth Israel Deaconess Medical Center, Stroke Division, 330 Brookline Avenue Palmer 127, Boston, MA 02215, USA
    Stroke 42:3067-74. 2011
    Treatment with the iron chelator, deferoxamine mesylate (DFO), improves neurological recovery in animal models of intracerebral hemorrhage (ICH)...
  77. ncbi A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy
    Naoshi Kubota
    First Department of Internal Medicine, Second Department of Pathology, Tokyo Medical University
    Haematologica 88:EIM13. 2003
  78. ncbi Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy
    Annita Kolnagou
    Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus
    Eur J Haematol 85:430-8. 2010
    ..New chelating drug protocols are necessary to treat completely transfusional iron overload and eliminate associated toxicity. Appropriate deferiprone/deferoxamine combinations could achieve this goal.
  79. ncbi Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy
    Carlos A Obejero-Paz
    Rammelkamp Center for Education and Research, MetroHealth Campus, Cleveland, OH 44109, USA
    J Lab Clin Med 141:121-30. 2003
    ..ECG) changes in the Mongolian gerbil model of iron overload and the effects of the iron chelator deferoxamine (DFO) on these changes...
  80. ncbi Barriers to adherence of deferoxamine usage in sickle cell disease
    Marsha J Treadwell
    Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
    Pediatr Blood Cancer 44:500-7. 2005
    We hypothesized that child cognitive disability would be a significant risk factor for non-adherence with home deferoxamine (DFO) administration and that a factor that would contribute to improved adherence would be sharing of ..
  81. ncbi Deferoxamine reduces and nitric oxide synthase inhibition increases neutrophil-mediated myotube injury
    Thomas J McLoughlin
    Skeletal Muscle Physiology Laboratory, The University of Toledo, Toledo, OH 43606, USA
    Cell Tissue Res 313:313-9. 2003
    ..A significant protective effect was provided by including catalase (600-2400 U/ml), deferoxamine (1-2 mM), or anti-CD18 antibody (10 microg/ml) in the culture medium...
  82. ncbi Iron chelation adherence to deferoxamine and deferasirox in thalassemia
    Felicia Trachtenberg
    New England Research Institutes, 9 Galen Street, Watertown, MA 02472, USA
    Am J Hematol 86:433-6. 2011
    The Thalassemia Clinical Research Network collected adherence information from 79 patients on deferoxamine and 186 on deferasirox from 2007 to 2009...
  83. pmc Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia
    Yingqi Xing
    Department of Neurosurgery, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109 2200, USA
    Brain Res 1291:113-21. 2009
    ..This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia...
  84. ncbi Effects of deferoxamine on blood-brain barrier disruption and VEGF in focal cerebral ischemia
    Oak Z Chi
    Department of Anesthesia, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 125 Paterson Street, Suite 3100, New Brunswick, NJ 08901 1977, USA
    Neurol Res 30:288-93. 2008
    b>Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain ..
  85. ncbi Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats
    A M Emara
    Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Tanta University, Egypt
    Hum Exp Toxicol 25:375-85. 2006
    ..Although the beneficial effects of deferoxamine (DFO) on iron-associated mortality are well documented, the role of deferiprone in the management of ..
  86. ncbi Desferrioxamine related maculopathy: a case report
    Anita Arora
    The Western Eye Hospital, London, United Kingdom
    Am J Hematol 76:386-8. 2004
    ..To avoid such complications an ophthalmic screening has been suggested for patients taking desferrioxamine. We report an 81-year-old patient who developed irreversible ocular toxicity despite undergoing ophthalmic screening...
  87. ncbi Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study
    Paolo Ricchi
    Dipartimento di Oncoematologia, UOC Centro delle Microcitemie A Mastrobuoni, AORN A Cardarelli, Naples, Italy
    Eur J Haematol 85:36-42. 2010
    ..We retrospectively evaluated the efficacy of different schedules of combined chelation therapy and the incidence of adverse events...
  88. ncbi Deferoxamine pretreatment prevents Cr(VI)-induced nephrotoxicity and oxidant stress: role of Cr(VI) chelation
    Eduardo Molina-Jijón
    Faculty of Chemistry, Department of Biology, National Autonomous University of Mexico UNAM, University City, 04510, D F, Mexico
    Toxicology 291:93-101. 2012
    b>Deferoxamine (DFO) is a recognized iron chelator which has been shown to exert nephroprotection in models of toxic nephropathies...
  89. ncbi Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity
    Fatih Bulucu
    Department of Internal Medicine, Gulhane Military Medical Academy, Ankara, Turkey
    Biol Trace Elem Res 132:184-96. 2009
    ..by doxorubucin (DOX) and to compare the possible protective effects of N-acetylcysteine (NAC) (n=10), deferoxamine (DOF) (n=10), DOF+NAC (n= 10) and selenium (n=9) on doxorubicin-induced hepatotoxicity...
  90. ncbi Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
    Caterina Borgna-Pignatti
    Department of Pediatrics, University of Ferrara
    Haematologica 89:1187-93. 2004
    ..The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed...
  91. ncbi Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs
    Demetrios Vlahakos
    Department of Internal Medicine, Athens University Medical School, Attikon University Hospital, Haidari, Athens, Greece
    Artif Organs 36:400-8. 2012
    We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute ..
  92. ncbi Treatment with deferoxamine increases neurons from neural stem/progenitor cells
    Hye Jung Kim
    Department of Neurophysiology and Brain Science, Nagoya City University Graduate School of Medical Sciences, Mizuho ku, Nagoya 467 8601, Japan
    Brain Res 1092:1-15. 2006
    ..Treatment of NPCs with deferoxamine, a G1/S phase blocker, increased the number of beta-tubulin III-positive cells after differentiation, ..
  93. pmc Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload
    Maya Otto-Duessel
    Division of Pediatric Cardiology, Department of Cardiology, Children s Hospital Los Angeles, Los Angeles, Calif 90027, USA
    Acta Haematol 120:123-8. 2008
    Combined therapy with deferoxamine (DFO) and deferasirox (DFX) may be performed empirically when DFX monotherapy fails...
  94. ncbi Tandem mass spectrometry of coprogen and deferoxamine hydroxamic siderophores
    Ana V C Simionato
    Laboratório de Cromatografia, Instituto de Quimica de Sao Carlos, Universidade de Sao Paulo, Av Trabalhador Saocarlense, 400 São Carlos, SP 13566 590, Brasil
    Rapid Commun Mass Spectrom 20:193-9. 2006
    ..Standard siderophores (e.g. deferoxamine and coprogen) were directly injected into both ion trap and linear quadrupole mass spectrometers with ..
  95. ncbi A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
    M A Tanner
    Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, Sydney St, London SW3 6NP, UK
    Circulation 115:1876-84. 2007
    ..Approximately two thirds of patients maintained on the parenteral iron chelator deferoxamine have myocardial iron loading...
  96. ncbi Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats
    Y Li
    Institute of General Surgical Research, Second Affiliate Hospital, Yangzhou University No 2 Clinical Medical College, Yangzhou, China
    Transplant Proc 43:1450-5. 2011
    b>Deferoxamine mesylate is known to ameliorate tissue ischemia-reperfusion injury...
  97. ncbi Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
    Caterina Borgna-Pignatti
    Clinica Pediatrica Università di Ferrara, Dipartimento di Medicina Clinica e Sperimentale, Via Fossato di Mortara 17 19, 44100 Ferrara, Italy
    Blood 107:3733-7. 2006
    b>Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients...
  98. ncbi Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators
    Annita Kolnagou
    Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus
    Hemoglobin 30:239-49. 2006
    ..therapy protocol involving the administration of deferiprone (L1) during the day (80-110 mg/kg/day) and deferoxamine (DFO) (40-60 mg/kg at least 3 days/week) during the night for 8-12 hours using a pump, or the whole 24 hours ..
  99. ncbi Exposure of rat thymocytes to hydrogen peroxide increases annexin V binding to membranes: inhibitory actions of deferoxamine and quercetin
    Y Oyama
    Laboratory of Cellular Signaling, Faculty of Integrated Arts and Sciences, The University of Tokushima, Minami Jyosanjima 1 1, Tokushima, Japan
    Eur J Pharmacol 384:47-52. 1999
    ..Therefore, it is likely that Ca(2+) is involved in the H(2)O(2)-induced cytotoxicity. Deferoxamine was effective to protect the cells suffering from H(2)O(2)-induced oxidative stress, suggesting a contribution ..
  100. ncbi Feasible identification of Staphylococcus epidermidis using desferrioxamine and fosfomycin disks
    Ana Lúcia Souza Antunes
    Fundacao Faculdade Federal de Ciencias Medicas de Porto Alegre, Port Alegre, Brasil
    APMIS 116:16-20. 2008
    ..In conclusion, the method proposed here has proved to be useful for the identification of S. epidermidis, the most frequent species of CoNS isolated from blood cultures in clinical microbiology laboratories...
  101. ncbi Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients
    A Taher
    The Chronic Care Centre, The American University of Beirut Medical Centre, Beirut, Lebanon
    Eur J Haematol 67:30-4. 2001
    Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease...

Research Grants63

  1. Role of SLc11a1 Gen in Warm Ischemia-Reperfusion Injury
    Samuel Wyllie; Fiscal Year: 2006
    ..If disruption Slc11a1 protects the liver from I/R injury by modulating mediation of iron homeostasis, then deferoxamine pretreatment of Slc11a1+/+ mice before I/R injury should protect the liver from I/R mediated injury, as ..
  2. Prevention of Complications in Thalassemia
    Elliott P Vichinsky; Fiscal Year: 2011
    ..Examples of current research hypotheses under investigation include: 1) Deferoxamine (DFO) and deferiprone (L1) combination therapy improves left ventricular function more rapidly than DFO/placebo ..
  3. Enhanced iron removal with peptide linked chelators targeted to ferritin
    Elizabeth C Theil; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: Current iron chelation therapy such as deferoxamine (DFO) relies on chelators inspired by bacterial siderophores intended to retrieve biologically available iron...
  4. Prevention and Treatment of Chlorine Gas Induced Injury to the Pulmonary System
    Sadis Matalon; Fiscal Year: 2011
    ..Thus, systemic administration of reactive species scavengers (such as ascorbate, N-acetyl-cysteine (NAC), and deferoxamine, as well as agents that augment surfactant levels, ion transport and paracellular resistance (such as albuterol ..
  5. Transdermal Delivery of Deferoxamine to Prevent and Treat Diabetic Wounds
    Geoffrey C Gurtner; Fiscal Year: 2011
    ..We have previously demonstrated that systemic delivery of the small molecule deferoxamine (DFO) is suficient to stabilize HIF-11 in diabetic models, resulting in improved wound healing and decreased ..
  6. Mechanisms of Brain Injury after Intraventricular Hemorrhage
    Guohua Xi; Fiscal Year: 2013
    ..areas following IVH;4) Intraventricular injection of iron alone can also result in acute hydrocephalus;5) Deferoxamine, an iron chelator, reduces IVH-induced hydrocephalus and hippocampal tissue loss...
  7. Intranasal deferoxamine to treat stroke in young and older, male and female rats
    SAMUEL SCOTT PANTER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The goal of the proposed study is to determine whether deferoxamine (DFO), administered via the intranasal (IN) route following stroke, provides neuroprotection against long-lasting functional ..
  8. Mechanisms of early brain injury after subarachnoid hemmorrhage
    Guohua Xi; Fiscal Year: 2013
    ..Our recent studies have demonstrated: 1) Brain iron overload occurs in a rat model of SAH;2) Deferoxamine, an iron chelator, reduces SAH-induced iron overload, oxidative stress and mortality;3) The complement cascade ..
  9. Hepcidin Replacement Therapy for Iron Overload Disorders
    James W Larrick; Fiscal Year: 2013
    ..in an otherwise-healthy person consists of regularly scheduled phlebotomies or iron-chelating agents like deferoxamine. Most types of iron overload are associated with low levels of hepcidin, a peptide that regulates iron ..
  10. Stroke with Transfusions Changing to Hydroxyurea
    Russell E Ware; Fiscal Year: 2010
    ..b>Deferoxamine (Desferal(r)) chelation therapy is difficult to tolerate and leads to non-compliance an alternative to ..
  11. Iron Uptake and Mucormycosis Pathogenesis
    Ashraf S Ibrahim; Fiscal Year: 2013
    ..Patients with elevated levels of available serum iron such as those with DKA or who have received deferoxamine are uniquely susceptible to mucormycosis, but not other fungal infections...
  12. Combined Therapy for Intracerebral Hemorrhage Treatment
    Kenneth R Wagner; Fiscal Year: 2013
    ..In this regard, recent findings demonstrate the effectiveness of iron chelation with deferoxamine in improving outcome following ICH...
  13. Stroke with Transfusions Changing to Hydroxyurea (SWITCH) Trial Data Coordinating
    Ronald W Helms; Fiscal Year: 2010
    ..b>Deferoxamine chelation therapy is difficult to tolerate...
  14. Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (Hi-DEF)
    Magdy H Selim; Fiscal Year: 2013
    ..secondary neuronal injury after intracerebral hemorrhage (ICH);and that treatment with the iron chelator, deferoxamine (DFO), provides neuroprotection in animal models of ICH...
  15. Optimization of the angiogenic potential of multipotent adult progenitor cells
    Robert Deans; Fiscal Year: 2010
    ..we propose to investigate increasing the angiogenic benefit of MultiStem by the use of a small molecule, DFO (Deferoxamine Mesylate)...
  16. Twice-Weekly Subcutaneous Liposome Chelator to Treat Transfusional Iron Overload
    MARK EAMON HAYES; Fiscal Year: 2013
    ..The formulation will be easier and safer to administer than Desferal(R). If LDFO is validated, it would be a significant advance for the clinical treatment of transfusional iron overload in pediatric patients. ..
  17. Deferoxamine therapy for intracerebral hemorrhage
    Guohua Xi; Fiscal Year: 2010
    ..In particular, we found that systemic administration of the iron chelator deferoxamine can reduce ICH-induced brain injury in adult male rats...
  18. Cardiac Function and Cardiac iron (T2*) in Thalassemia
    John Wood; Fiscal Year: 2007
    ..While daily iron chelation therapy with subcutaneous deferoxamine ameliorates much of the iron toxicity, deadly iron cardiomyopathy still remains the norm, usually in the 3 rd ..
  19. CORNEAL-EPITHELIAL NUCLEAR FERRITIN AND U.V. PROTECTION
    THOMAS FRANK LINSENMAYER; Fiscal Year: 2013
    ..also allows the manipulation of synthesis of ferritin and ferritoid in CE cells by using the iron chelator deferoxamine - which reversibly blocks the synthesis of both components...
  20. PATHOGENESIS OF MINERAL DUST TOXICITY
    Agnes Kane; Fiscal Year: 1991
    ..Asbestos toxicity in vitro or in vivo is prevented by free radical scavenging enzymes or the iron chelator, deferoxamine. It is hypothesized that oxidant-induced stress directly or indirectly disrupts intracellular calcium ..
  21. MECHANISMS OF MYOCARDIAL REPERFUSION INJURY
    MERVYN FORMAN; Fiscal Year: 1991
    ..to determine whether restoration of scavenging enzymes will reduce reperfusion injury, and the iron chelator Deferoxamine to clarify whether iron is an essential contributor to lipid peroxidation in vivo...
  22. CULTURED CARDIAC MYOCYTES--A MODEL OF IRON OVERLOAD
    Chaim Hershko; Fiscal Year: 1991
    ..contractility and electrophysiologic behaviour and increased peroxidation of membrane lipids, reversible by deferoxamine treatment...
  23. A Novel Antibody Therapeutic for Multiple Myeloma
    Koteswara Chintalacharuvu; Fiscal Year: 2009
    ..to evaluate the additive/synergistic effect of the combination of anti-hTfR IgA and the iron-chelating agent deferoxamine (DFO) in model multiple myeloma cell lines...
  24. METHODS FOR PCR SAMPLE PREPARATION--HEME NEUTRALIZATION
    Lily Lin; Fiscal Year: 1991
    ..b>Deferoxamine will also be attempted, however, this is another agent known not to bind to heme iron or to remove iron from ..
  25. INHIBITION OF INTESTINAL HEME IRON ABSORPTION
    JERRY BOMMER; Fiscal Year: 2007
    ..for iron overload syndromes include phlebotomy (in non-anemic cases) and subcutaneous continuous infusions of deferoxamine. The latter treatment would be rendered more effective or unnecessary if intestinal iron absorption could be ..
  26. Zinc Metabolism in Plasmodium Falciparum
    Oluwatosin Gisanrin; Fiscal Year: 2005
    ..Many metal chelators for example deferoxamine, an intravenous clinical iron chelator, also kill the parasite...
  27. Thalassemia Clinical Research Network, Canada
    Nancy Olivieri; Fiscal Year: 2009
    ..Two trials are proposed. First, a randomized, controlled trial to examine the effect of deferoxamine alone v. deferoxamine plus deferiprone, on cardiac disease due to transfusional iron overload...
  28. THALASSEMIA CLINICAL RESEARCH NETWORK
    Janet Kwiatkowski; Fiscal Year: 2009
    ..Two trials are proposed. First, a randomized, controlled trial to examine the effect of deferoxamine alone v. deferoxamine plus deferiprone, on cardiac disease due to transfusional iron overload...
  29. FERRIC ION SEQUESTERING AGENTS--IRON REMOVAL
    Kenneth Raymond; Fiscal Year: 1999
    ..Preliminary toxicity studies will be carried out in collaboration with Dr. P. Durbin. Screening for iron removal will be carried out for the most promising compounds in collaboration with Dr. R. Bergeron. ..
  30. HYPEROXIA, DRUG ANTIOXIDANTS & LUNG MACROPHAGE INTEGRITY
    Michael Sherman; Fiscal Year: 1990
    ..oxidant injury by decreasing hydrogen peroxide production via the cytochrome P-450 oxygenase system, and 2) deferoxamine blocks hydroxyl and perferryl radical production in metal-catalyzed reactions, thereby reducing oxidant injury ..
  31. MODELING OF MIXED LIGAND THERAPY FOR IRON OVERLOAD
    Robert Hider; Fiscal Year: 2002
    ..With the most widely evaluated drugs, deferoxamine and deferiprone, only 10% and 4% respectively of the drugs are excreted in the iron bound form when given to ..
  32. Hypoxia Signaling, Chromatin Remodeling and Nickel Carcinogenesis
    Max Costa; Fiscal Year: 2009
    ..We will study the ability of hypoxia and agents that activate hypoxia signaling (NiCI2, CoCI2, deferoxamine, and DMOG) to induce cell transformation in wild-type or in HIF-1alpha knockout mouse embryo fibroblast (MEF)...
  33. MECHANISMS AND PREVENTION OF HEMOGLOBIN NEUROTOXICITY
    SAMUEL PANTER; Fiscal Year: 2002
    ..Finally, animals will be pretreated with an antioxidant (polynitroxyl-albumin), an iron chelator (a starch deferoxamine conjugate), the normal hemoglobin-binding protein haptoglobin, or a subfraction of pentastarch that has been ..
  34. NEUROPROTECTIVE GENE INDUCTION BY ANTIOXIDANT IRON CHELA
    Rajiv Ratan; Fiscal Year: 2002
    ..In preliminary studies, we have found that structurally distinct iron chelators, deferoxamine mesylate, and mimosine prevent apoptosis induced by glutathione-depletion and oxidative stress in embryonic ..
  35. THALASSEMIA CLINICAL RESEARCH NETWORK
    Patricia Giardina; Fiscal Year: 2009
    ..Two trials are proposed. First, a randomized, controlled trial to examine the effect of deferoxamine alone v. deferoxamine plus deferriprone, on cardiac disease due to transfusional iron overload...
  36. THERAPEUTIC MULTIDENTATE IRON SEQUESTERING AGENTS
    Kenneth Raymond; Fiscal Year: 2007
    ..Several new ligand types are proposed with specific hypotheses about structural function relationships. [unreadable] [unreadable]..
  37. SIDEROPHORES, ANALOGS AND BIOCONJUGATES
    Marvin Miller; Fiscal Year: 1999
    ..5) Perform detailed biological studies to determine the mode of action of antimicrobial siderphore analogs and conjugates to conform the feasibility of siderphore-mediated drug delivery and facilitate long term SAR studies. ..
  38. Intranasal Deferoxamine to Precondition Against Stroke
    SAMUEL PANTER; Fiscal Year: 2006
    ..The drug we have chosen to use-deferoxamine (DFO)-has been demonstrated to precondition in a number of experimental systems, from cell culture to neonatal ..
  39. Tumor Induced Dysregulation of T Cell Immunity
    James H Finke; Fiscal Year: 2010
    ..The observation that the anti-oxidant deferoxamine (DFO) can block ganglioside-mediated apoptosis of T cells will be studied further to define how DFO protects T ..
  40. SELECTIVE ORAL CHELATORS FOR IRON OVERLOAD DISEASES
    Urszula Slomczynska; Fiscal Year: 2000
    ..At present the drug of choice is deferoxamine, which must be administered by injection, has a short half-life, and is known to have toxic side effects...
  41. MACROMOLECULAR CONTRAST AGENTS FOR MAGNETIC RESONANCE
    Bo Hedlund; Fiscal Year: 1991
    BIOMEDICAL FRONTIERS (BMF) has establishes that the iron chelator, deferoxamine, can be covalently bound to polymers and has demonstrated, in preclinical studies, that these conjugates can be used therapeutically as antioxidants...
  42. IRON CLEARANCE BY TRANSFERRIN HALF-MOLECULES
    RICHARD JENNY; Fiscal Year: 1991
    ..The relative efficiencies of iron removal from these cells by (a) deferoxamine, (b) holoapotransferrins and (c) apotransferrin half-molecules separately and in combination, will be compared...
  43. Metal Ion is Critical in amyloid beta Induced JNK Activation
    Xiongwei Zhu; Fiscal Year: 2009
    ..we demonstrated that AB toxicity is significantly attenuated when AB is pretreated with the iron chelator deferoxamine, suggesting that iron augments AB toxicity...
  44. CARDIOPROTECTIVE EFFECT--NEW CHELATORS FOR THALASSEMIA
    Chaim Hershko; Fiscal Year: 2001
    ..abstract_text> ..
  45. Eighth Cooley's Anemia Symposium
    Elliott Vichinsky; Fiscal Year: 2005
    ....
  46. Modulation of Iron Deposition in SCD and Other Hemoglobinopathies
    ELLIOTT P contact VICHINSKY; Fiscal Year: 2010
    ....
  47. E/BETA THALASSEMIA--NATURAL HISTORY & RESPONSE TO CHEMO
    Elliott Vichinsky; Fiscal Year: 2002
    ..In summary, if this study is successful, it will change the approach to Hb E/B worldwide and result in improved quality of life and decreased mortality. (End of Abstract) ..
  48. ERYTHROCYTAPHERESIS TO LOWER IRON LOADING IN THALASSEMIA
    Alan Cohen; Fiscal Year: 2002
    ..Iron chelation therapy with deferoxamine removes excessive iron, but the need for parenteral administration of the chelator, drug-related side effects ..
  49. Treatment of Fungal Infections with ATAK Cells
    Ashraf Ibrahim; Fiscal Year: 2004
    ..Furthermore, the genetic construct targeting ATAK cells to Candida can easily be adapted to any other pathogen against which a MAb has been raised. ..
  50. Novel Antifungal Strategies for Lethal Mucormycosis
    Ashraf Ibrahim; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  51. L-GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA
    Yutaka Niihara; Fiscal Year: 2005
    ..Abstract Not Provided ..
  52. PROTECTIVE ROLE OF APOPTOSIS IN ASBESTOS PLEURAL INJURY
    V Broaddus; Fiscal Year: 2001
    ..These studies should provide important information about the mechanisms by which asbestos induces apoptosis in mesothelial cells and the role of asbestos-induced apoptosis in asbestos-induced pathology. ..
  53. Amplification of TRIAL-Indcued Apoptosis in Mesothelioma
    V Broaddus; Fiscal Year: 2006
    ..the mechanisms of amplification of TRAIL-induced apoptosis can provide insight into the means by which malignant cells evade apoptosis and ways to bypass those sites of resistance and thereby improve treatment strategies ..
  54. Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage
    Magdy H Selim; Fiscal Year: 2010
    ..injury and brain edema after intracerebral hemorrhage (ICH);and that treatment with iron chelators, such as deferoxamine (DFO), provides neuroprotection...
  55. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
  56. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ....
  57. VACCINE EFFICACY IN CHILDREN WITH SICKLE CELL DISEASE
    Thomas Adamkiewicz; Fiscal Year: 2006
    ..abstract_text> ..